Critical care and infectious disease specialist Innoviva Specialty Therapeutics Inc (IST), a subsidiary of Innoviva Inc (Nasdaq:INVA), revealed on Monday that it has secured exclusive US marketing rights to Zevtera (ceftobiprole) from Swiss biopharmaceutical R&D company Basilea Pharmaceutica Ltd (SIX:BSLN).
Zevtera is an advanced-generation cephalosporin antibiotic approved by the US Food and Drug Administration (FDA) for treating various bacterial infections, including MRSA.
Innoviva plans to commercialise Zevtera in the United States in mid-2025.
This acquisition strengthens Innoviva's product portfolio and expands its presence in the infectious disease market.
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Ireland selects Conduent to enhance infectious disease management
bioMérieux receives FDA clearance for VITEK COMPACT PRO to combat antimicrobial resistance
ANI Pharmaceuticals secures FDA approval for ILUVIEN label expansion
Kenox Pharmaceuticals partners with Lactiga US
Nona Biosciences signs licensing agreement with University of Alabama at Birmingham
ImmunityBio's ANKTIVA receives EMA review for BCG-unresponsive bladder cancer treatment
hVIVO signs LOI for landmark Phase 3 whooping cough vaccine trial with ILiAD Biotechnologies